Tofacitinib-induced remission in refractory adult-onset Still’s disease complicated by macrophage activation syndrome

Click to increase image sizeClick to decrease image size

Acknowledgement

The patient’s next of kin consented to this case report.

Disclosure statement

HM received speaking fees from Asahi Kasei and Ono. KM has received speaking fees from Eisai, Chugai, Mitsubishi-Tanabe, Bristol-Myers Squibb, Janssen, Astellas, Takeda, Nippon Kayaku, Daiichi-Sankyo, Asahi Kasei, and AbbVie Japan. MY has received grants from Asahi Kasei, Chugai, Ono, Daiichi-Sankyo, Teijin, Eisai, Nippon Kayaku, and Mitsubishi-Tanabe; instructor fees from Asahi Kasei, Kissei, and Janssen; and speaking fees from Ono, Mitsubishi-Tanabe, Astellas, UCB Japan, Chugai, AbbVie Japan, Daiichi-Sankyo, Ayumi, Janssen, Takeda, Sanofi, Teijin Pharma, Eli Lilly Japan, and Eisai. MM and KS have no conflicts of interest to declare.